Normal
0
false
false
false
EN-US
X-NONE
AR-SA
MicrosoftInternetExplorer4
Background: Routine oophorectomy in women with colorectal
cancer is under debate, the aim of this study is to determine
incidence, clinicopathologic features and prognostic factors of ovarian
involvement in primary colorectal cancer (CRC) and
to clear the role of prophylactic oophorectomy.
Methods: Data
from primary CRC women treated between years 1990 and 2004 were
retrieved and clinical and pathologic features of those who had undergone
oophorectomy during CRC surgery were reviewed.
Results: One
hundred eighty cases (mean age 47.5 years) were included. In 120(66.6%),
ovaries were preserved and 60(33.3%) cases underwent bilateral
oophorectomy in addition to primary CRC
resection. Reasons for oophorectomy were prophylactic in 22(36.6%),
abnormal morphology in 35(58.3%), and undetermined in 3(5%)
cases. There were five metastatic carcinomas, eight primary ovarian tumors and 47
normal ovaries in pathologic evaluation. No complication directly related to
oophorectomy was noted. Patients with ovarian metastases had higher stages of
tumor. Ovarian metastases were not related to menstrual status, CRC
location, size, differentiation, and mucin production, as well as abnormal
morphology of ovary. The global prevalence of ovarian metastasis in CRC was 2.7%, and
isolated ovarian metastases occurred in less than half of them. Of 120 women
that underwent colectomy alone, eight (6.6%)
developed ovarian metastasis during two years of follow-up. Only three cased
had isolated ovarian metastases. No patient with synchronous or metachronous
ovarian metastases from CRC survived five years.
Conclusion: Isolated ovarian metastases
from primary CRC occur with a low frequency
and this may partially explain the debate regarding prophylactic oophorectomy
at the time of curative resection for primary CRC.
Normal
0
false
false
false
EN-US
X-NONE
AR-SA
MicrosoftInternetExplorer4
Background: Insulin resistance is common in women with Polycystic
Ovary Syndrome
(PCOS) and can cause poor outcome of infertility
treatment. The aim of our study
was to assess the effect of treatment with metformin on outcome of Intra
Cytoplasmic Sperm
Injection (ICSI)
in infertile PCOS women.
Methods: A randomized clinical trial study was carried
out in infertile women with PCOS, before ICSI,
referred to infertility clinic of Mirza
Koochackhan Hospital
of Tehran University
of Medical Science
Tehran, Iran,
between 2006 and 2008.
The patients were randomized in two groups of
metformin 500 mg Po,
three times daily, six weeks before the ICSI
cycle and placebo patients in each group were divided into BMI
<28 kg/m2 and BMI
&ge28 kg/m2.
Results: Of 52
study women 26(50%) were in metformin
group. mean age were 29.8±4.9 year in
metformin group versus 29.4±5.9 year and
placebo groups. Treatment with
metformin, in subgroup of BMI <28 kg/m2,
significantly increased number of mature follicle (p=0.01),
embryo (p=0.04),
oocytes (p=0.007)
and mature oocytes (p=0.03)
but in subgroup of BMI&ge28 kg/m2,
there was no significant difference in the metformin and placebo groups (p>0.05).
Metformin treatment caused more chemical and
clinical pregnancy rates, and less abortion rate in overweight and normal patients,
but the differences were not significant (p>0.05).
Logestic regression analysis showed, adjusting
number of mature follicle, number of embryos, quality of embryos, oocytes and BMI
and treatment showed no significant effect on clinical pregnancy
rates (p>0.05).
Conclusions: Among normal weight PCOS
women, effect of treatment with metformin is better than overweight PCOS
women. However further
studies are needed.
Normal
0
false
false
false
EN-US
X-NONE
AR-SA
MicrosoftInternetExplorer4
Background: Diabetes is a metabolic disorder affecting the whole body systems including the
female reproductive organs. Moreover, diabetes is an important cause of
infertility. Metformin is commonly used to control hyperglycemia in patients
with diabetes. This study was done to evaluate the ultrastructural changes of
ovarian follicles in diabetic rats and their response to metformin.
Methods: Thirty-six adult Sprague-Dawley female rats (170-210
g) were studied in three groups (Control, diabetic and metformin-treated rats).
In the second and third groups, diabetes was induced by injection of
streptozotocin (45 mg/kg).
The rats in the third group were later treated by metformin monohydrochloride
(100 mg/kg). At the end of the experiment, rats
were sacrificed and their right ovaries were observed under transmission
electron microscope. Quantitative data were analyzed by student t-test in SAS
software.
Results: In comparison with the control group, significant decreases in zona pellucida
thickness and the mean number of microvilli were observed (respectively, P<0.01
and P<0.001) in diabetic rats. Significant
decreases in zona pellucida thickness were also observed in metformin-treated
rats (P<0.05) but changes in the number of
microvilli were non-significant. The number of organelles in oocyte cytoplasm
was higher and they were natural or natural-looking in metformin-treated rats
versus the diabetic ones. Reduction in the number of mitochondria and their
ballooning cristae were of the most noticeable changes in diabetic rats.
Conclusion: Diabetes
decreases the number of microvilli and oocyte organelles and diminishes zona
pellucida thickness leading to structural changes in the organelles but
metformin could improve the aforesaid conditions.
Normal
0
false
false
false
EN-US
X-NONE
AR-SA
MicrosoftInternetExplorer4
Background: Cyclooxygenase 2 is a key enzyme which converts arachidonic acid into
prostaglandins. Cyclooxygenase 2 is triggered by
inflammatory stimuli, such as cytokines. Its expression increases in tumors and
Alzheimer's disease and ovarian hyperstimulation syndrome. Polycystic ovarian
syndrome is a heterogeneous disease characterized by pathological angiogenesis
and chronic anovulation. In the present study, the probable role of
cyclooxygenase 2 in Wistar rats with polycystic
ovarian syndrome was investigated.
Methods: Thirty
female Wistar rats (170-200 gr)
were equally divided into three groups: 2 mg
estradiol valerate was intramuscularly administered to each rat in the
experiment group or group 1 the rats in group 2 were regarded as the sham group and received sesame oil
injections and group 3 or the control group received no
injections. After 60 days of treatment, animals were
anaesthetized with chloroform and killed by decapitation. Ovaries were
collected for histological and immunohistochemical evaluations. All the
experiments were repeated three times.
Results: Morphologically, ovaries from the
control group exhibited follicles in various stages of development and many
fresh corpus luteum. In estradiol valerate group small follicles in early
development were observed in addition to follicles showing evidence of atresia
and many large cysts with thickened theca cell layer. Corpus luteum was rare or
absent in group 2. The immunohistochemical analysis
for cyclooxygenase 2 expression showed an increased
expression of cyclooxygenase 2 enzyme in group 1.
Conclusion: The results suggested the involvement of
cyclooxygenase 2 in
the progression to polycystic ovarian syndrome in a rat model.
Background: Endothelial dysfunction can influence fertility rate in women with polycystic ovary syndrome (PCOS) as flow mediated dilatation (FMD) is impaired in patients with the disease. The aim of this study was to compare two methods of ovulation induction by letrozole or letrozole plus human menopausal gonadotropins (HMGs) in infertile women with PCOS who were resistant to clomiphene citrate based on brachial artery ultrasound findings.
Methods: In this double -blind randomized clinical trial, 59 infertile women who had the inclusion criteria for PCOS were evaluated in the Infertility Clinic of Shariati Hospital in Tehran, Iran in 2010-2011. The patients were assigned to two letrozole and letrozole plus HMG groups and were evaluated for FMD in the brachial artery by transvaginal ultrasonography. Later, the values were recorded and analyzed statistically.
Results: In the letrozole group, infertility treatment was successful in 15 (57.7%) but it failed in 11 (42.3%) patients. In letrozole plus HMG group, the treatment was successful in 18 (54.5%) while it failed in 15 (45.5%) patients. The mean FMD values in the groups with successful and unsuccessful treatment results were 19.42±10% and 18.57±7.2%, respectively, but the difference was not statistically significant (P=0.712). Moreover, the average endometrial thickness in groups with successful and unsuccessful treatment results were 8.4±1.3 mm and 9.8±3.9 mm, respectively but the difference was not significant either (P=0.06).
Conclusion: In infertile women with polycystic ovary syndrome that are resistant to clomiphene, letrozole or letrozole combined with gonadotropin can be equally effective for ovulation induction.
Background: Steroid cell tumor is one of the rare ovarian tumors and forms 0.1% of all ovarian tumors, divided to three subgroups. Steroid cell tumor that are not otherwise specified (NOS) are the most common type and represent 60% of steroid cell tumors. One of the most known signs of this tumor is hormonal function, especially androgenic effects of it. Primary treatment consists of eradication of tumor via surgery.
Case presentation: The patient is a 29 years old female with history of poly cystic ovarian syndrome since 10 years ago, who attended to the clinic of General Women Hospital of Tehran in January 2011. In pelvic ultrasonography, there was a 6449mm mass in the right adnexa consisting of homogeneous component. She underwent laparotomy and unilateral salpingoophorectomy was done. Pathological report was steroid cell tumor of ovary.
Conclusion: The aim of this study is reporting one of the rare tumors of ovary and assessment of the correct way of diagnosis and treatment of it.
Background: Polycystic ovary syndrome (PCOS) is a common complex condition. Evidences from studies on women with PCOS and rat PCO model suggest that the sympathetic regulatory drive to the ovary may be unbalanced (hyperactivity). Findings that support the involvement of sympathetic nervous system in the pathophysiology of PCOS are that the catecholaminergic nerve fibers in the polycystic ovaries of women with PCOS are denser than in normal ovaries. The purpose of this study was reduction of this hyperactivity.
Methods: This study was clinical trial and was performed in Reproductive Health Research Center, Tehran University of Medical Sciences, Iran, during January 2013 to 2015. A total of 61 women between aged 20-40 years and BMI under 28 kg/m2, who were previously diagnosed with PCOS were assessed. The diagnosis of PCOS was made according to joint criteria of the European Society of Human Reproduction and Embryology and the American Society of Reproductive Medicine (ESHRE/ASRM). The study objectives were explained to the patients before they entered the study, and an informed consent was obtained from all. They were divided into three groups as follows: (i) two study group (n=39) and (ii) control group (n=22). For evaluating effects of alpha-2 inhibitors (Clonidine and Yohimbine) by Eliza, the following variables were evaluated before and after drug therapy: serum cortisol adrenaline (A) noradrenalin (NA) beta-endorphin (&beta-End) insulin as well as sex hormones including FSH, LH and Estradiol.
Results: Our results showed that, Clonidine as central anti-adrenergic drug causes 61% of all pregnancies in the study group. This is high percentage of the pregnancy rate compared with yohimbine (P< 0.001). Yohimbine (Indol alkaloid) as alpha-2 adenoceptor antagonist increases follicular development in this disease. This follicle growth is higher than clonidine (P< 0.01).
Conclusion: Our findings showed that increasing the pregnancy rate and follicular development represent the strategic role of sympathetic nervous system (SNS) in polycystic ovary syndrome and) SNS may thus offer a novel biological and pharmacological target in treatment of PCOS.
Background: Polycystic ovary syndrome (PCOS) is the most common endocrine disorders in reproductive age women. These women confer with complications of pregnancy such as gestational diabetes, pregnancy-induced hypertension, preeclampsia and neonatal complications such as small for gestational diabetes (SGA) are more prevalence in women with PCOS. The aim of this study was to evaluate the incidence of complications associated with PCOS in pregnant women.
Methods: This was an observational and prospective study which recruited 205 pregnant women with PCOS from Imam Khomeini Hospital, Ahvaz Jundishapur University of Medical Sciences (AJUMS) between 2013 and 2014. Inclusion criteria were women with PCOS and gestational age over 20 weeks. The demographic and clinical variables including mother's age, body mass index (BMI) and conditions of pregnancy including pregnancy-induced hypertension, preeclampsia, gestational diabetes and overt diabetes and neonatal complications such as preterm labor (PTL), SGA and intrauterine fetal death (IUFD) were recorded.
Results: The prevalence of hypertension disorders, preeclampsia, gestational diabetes and overt diabetes were observed in 44 (21.5%), 18 (8.8%), 29 (14%) and 22 (11%) patients, respectively. The history of familial diabetes was shown in 28 patients (13.6%). In addition, the history of pregnancy induced hypertension was reported in 25 patients (12.1%). Only 6 patients (2.9%) had history of gestational diabetes. Among neonatal complications due to PCOS, SGA with 15.3% and then PTL with 12.6% had highest prevalence. IUFD was shown only in 2 patients.
Conclusion: Pregnant women with PCOS are at the higher risk for pregnancy and neonatal complications. Specifically, these women should be evaluated for pregnancy induced hypertension during pregnancy than others.
Background: Infeliximab is a form of chimeric antibody which neutralizes the most important inflammatory cytokine, TNF-a, in inflammatory disorders. The aim of current study was to pilot expression of chimeric infliximab in Chinese Hamster ovary (CHO) cells.
Methods: In this research study, pVITRO2-neo-mcs vector that consist of infliximab light chain and heavy chain was used to transform into the E.coli by CaCl2 method. The plasmid was then purified and transfected to cultured CHO cells by Lipofectamine 2000® (Invitrogen GmbH, Germany). Transfected cells were selected upon G-418 treatment after 2 weeks and the level of expression, based on standard curve, was measured using IgG ELISA kit after 48 hours for each clone. High level expressed clone was then cultured in roller bottles and recombinant chimeric product was purified by protein A affinity chromatography. The purity of the product was analyzed by 10% gel SDS-PAGE from eluted samples. The efficacy of the purification was analyzed by ELISA before and after purification step. This article is a master's student thesis from February 2015 to August 2016 in pharmaceutical technology development center, Tehran University of Medical Sciences, Tehran, Iran.
Results: The purified plasmid was analyzed on 2% agarose gel. After selective pressure of G-418, 10 stable transfect clones were assessed for infliximab secretion by IgG ELISA kit at 450 nm. The maximum and minimum expression which detected by ELISA were 23 ng/ml and 6 ng/ml, respectively. The band width of infliximab fraction during purification procedure was observed at 0.7-0.8 min. The efficiency of the purification by ELISA was 70%. On SDS-PAGE analysis, two bands, 25 and 50 kDa, respect to light and heavy chains of Infliximab, was confirmed the expression of recombinant protein.
Conclusion: In the current study, the construct for infliximab monoclonal antibody production was designed using genetic engineering techniques and the expression was confirmed by conventional molecular biology methods. The high yield production was carried out in semi-industrial scale using roller bottles with a 70 percentage of purification efficiency.
Background: Polycystic ovary syndrome (PCOS) is a common complex condition in women associated with reproductive and metabolic systems and also psychological disorders. There is considerable evidence to suggest that the sympathetic nervous system is involved in PCO and metabolic syndromes. Noradrenalin (NA), corticotrophin releasing hormone (CRH) and nerve growth factor (NGF) are the strong stimulants for two axes: hypothalamic-pituitary-adrenal (HPA) and hypothalamic-pituitary-ovarian (HPO) axes which are regulators for the female reproductive system. Following previous studies on sympathetic nervous system over activity in PCOS, the main purpose of this study is to evaluate the role of CRH and NGF as two important findings from the perspective of the psycho-emotional.
Methods: This case-control study was conducted in Reproductive Health Research Center of Imam Khomeini Hospital, Tehran, Iran in the September of 2011. 170 women participated in this study. The diagnosis of PCOS was made according to the joint criteria of the European Society of Human Reproduction and Embryology and the American Society of Reproductive Medicine (ESHRE/ASRM). All women have 20-40 years of age and body mass index (BMI) of less than 28. Demographic questionnaire was used in this study and blood sample was obtained from all participants before 8AM. All analysis was done in SPSS software, version 19 (IBM SPSS, Armonk, NY, USA). P-value less than 0.05 considered as significant level.
Results: Serum levels of CRH and NGF in patients with polycystic ovary was significantly lower than the control group (P< 0.001). This reduction can disrupt two neural axes: the sympathetic nervous system (SAS) and hypothalamus-pituitary-adrenal (HPA). These axes have a fundamental role in psycho-emotional reactions in women with PCOS. Moreover, using demographic questionnaire quantitative and qualitative characteristics of the population studied, the results of which are reported in the regression model.
Conclusion: The results of this study confirmed previous studies. This reduction in serum levels of CRH and NGF shows the hyperactivity of sympathetic nervous system in polycystic ovary syndrome can be one of the causes of mental disorders in women with PCOS.
Background: Clomiphene citrate is very successful in inducing ovulation; there is usually a discrepancy between ovulation and pregnancy rate. If treatment is started early in the cycle this negative effect is reduced. The aim of this study was to investigate the effect of the time of administration of clomiphene citrate on follicular growth, endometrial thickness and ovulation and pregnancy rates in PCOS (Polycystic ovary syndrome) patients.
Methods: This randomized controlled trial study was performed on 115 PCOS (Polycystic ovary syndrome) women in Fateme Zahra Fertility and Infertility Research Health Center in April 2012. Patients randomly divided into two groups. Patients in the early group (No. 55) received 100 milligrams of clomiphene citrate tablet daily starting the next day after finishing medroxyprogesterone acetate tablet for 5 day, whereas the patient in the late group (No. 60) received 100 milligrams of clomiphene citrate tablet daily for 5 day starting on day 3 of the menstrual cycle. Then on follicular growth, endometrial thickness and ovulation and pregnancy rates by SPSS software, version 16 (Armonk, NY, USA) were compared in two groups. Results: 36.4% of patients of early administration of clomiphene and 60% of patients in the later administration of Clomiphene were able to build dominant follicle. This difference was statistically significant (P<0.011). There was no statistically significant difference between the two groups on age, body mass index, duration of infertility. Findings showed that in the early group 14 (63.6%) and in the late groups 8 (36.4%) women who made dominant follicle, were pregnant. There was significant difference between these two groups (P<0.001). But, in the number of follicles, endometrial thickness and pregnancy rate, there were no significant difference. In the early administration of clomiphene, the pregnancy rate was 25.5%. However in the later administration of clomiphene it was 13.3% (P=0.882). Conclusion: According to the results of this study, if the dominant follicle was made, with administration of clomiphene citrate in luteal phase the incidence of successful pregnancy is higher. |
Results: The mean weight and BMI (P=0.002), hirsutism and irregular menstruation cycle in the study group were greater than the control (P<0.001). In the study group the mean score of the sleep questionnaire in three dimensions: sleep problems (P=0.024), drug use (P=0.048), and the sufficiency of sleep (P=0.049) were higher than control.
Regression analysis showed that there is a significant relationship between quality of life and menstruation cycle (P=0.046), as well as the three dimensions of negative affecting situations with family income (respectively, 0.015, 0.016 and P=0.035). Conclusion: The environmental factors can easily affect the quality of life in PCO women. Sleep patterns were not favorable, and the effect of menstruation on mood and low family income caused negative emotions in women with PCOS. |
Results: The age range of patients who were diagnosed with mature cystic teratoma of the ovary in the final pathology was 14-71 years. Most cysts were 5-10 cm in size. 86% of patients had unilateral right-sided ovarian involvement. The most common components of this cyst in the macroscopic report were hair (81%) and fat (80%). The diagnostic value of ultrasound for the diagnosis of mature teratoma of the ovary was 74.5%. The frozen section was used to diagnose and rule out the malignancy in 32.5% of patients.
|
|
Page 1 from 1 |
© 2024 , Tehran University of Medical Sciences, CC BY-NC 4.0
Designed & Developed by : Yektaweb